Assurance de qualité pour le cancer rectal – phase 2 ...

More documents

Recommendations

Info

110 PROCARE – phase 2 KCE reports 81Substance name ATC code CNKpublicCNK amb andhospRIZIV/INAMIcode100mgEloxatin Pulv Sol IV 5mg/ml L01XA03 1537802 767236 0026432450mgEloxatin Inj IV 5mg/ml 10ml L01XA03 784264 00607561Eloxatin Inj IV 5mg/ml 20ml L01XA03 784272 00607662UFTUFT Caps 28x100/224mg L01BC53 1626738 770586 00395575UFT Caps 42x100/224mg L01BC53 1620491 770586 00395474XelodaXeloda Comp 60x150mg L01BC06 1415314 768093 1415314Xeloda Comp 120x500mg L01BC06 1415322 768101 1415322PROPORTION OF PATIENTS IN WHOM A CEA WAS PERFORMEDBEFORE ANY TREATMENTMeasurement in prospective PROCARE database (Figure 26)CEA measurement before treatment is registered through variable ‘SPR_V148’. Patientsundergoing treatment are selected using the variables ‘AD_V111’, ‘AD_V113’,‘AD_V114’, ‘AD_V117’, ‘AD_V118’, ‘AD_V121’ and ‘AD_V122’ (hospital data sectionof data entry form).Similar to the distance from the anal verge, unavailability of CEA in the PROCAREdataset does not necessarily mean that the CEA was not measured, but that the CEAwas not registered.Measurement in coupled administrative database (Figure 27)Nomenclature codes are available for CEA measurement (Table 73). The date of firsttreatment is more difficult to identify and involves the identification of all possibletreatments through their specific nomenclature (surgery and radiotherapy) or ATCcodes (chemotherapy) (see previous QI).A timeframe of 3 months before the incidence date (which in most cases is the date ofbiopsy) was chosen, since in some cases the CEA measurement can be done before theactual diagnosis of rectal cancer (e.g. when ordered by the general practitioner duringthe diagnostic workup). Also, the incidence date (see appendix 3 for the definition) canbe the same as the date of first treatment, e.g. in case of emergency surgery.
KCE Reports 81 PROCARE – phase 2 111Figure 26. Algorithm for QI 1213 (PROCARE database).All patientsN=1071TreatmentN=1067N=894CEA83,79%Treatment(surgery-radiochemo)?CEA before firsttreatmentfilled out?NO CEAorCEA=missingin databaseorno questionnaire filled in(N=8)N=173No treatmentN=4Figure 27. Algorithm for QI 1213 (administrative database).All patientsN = 7074Did patient receivechemotherapy ORradiotherapy ORsurgery ?FalseN = 659N = 6337TrueMissingN = 78Is CEA performedbefore any treatment ?FalseN = 2139TrueN = 4198
Page 1 and 2:
Assurance de qualitépour le cancer
Page 3 and 4:
Assurance de qualité pour lecancer
Page 5 and 6:
KCE Reports 81B Cancer rectal - pha
Page 7:
KCE Reports 81B Cancer rectal - pha
Page 10 and 11:
vi Cancer rectal - phase 2 KCE Repo
Page 12 and 13:
2 PROCARE - phase 2 KCE reports 81A
Page 14 and 15:
4 PROCARE - phase 2 KCE reports 811
Page 16 and 17:
6 PROCARE - phase 2 KCE reports 81F
Page 19 and 20:
KCE Reports 81 PROCARE - phase 2 92
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70: KCE Reports 81 PROCARE - phase 2 59
Page 87 and 88: KCE Reports 81 PROCARE - Phase 2 77
Page 119: KCE Reports 81 PROCARE - phase 2 10
Page 169: KCE Reports 81 PROCARE - phase 2 15
Page 172 and 173:
Dépôt légal : D/2008/10.273/39
Page 174 and 175:
35. Etude relative aux coûts poten
show all

Assurance de qualité pour le cancer rectal – phase 2 ...

Create successful ePaper yourself

Delete template?

Save as template?